^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Ampulla of Vater Carcinoma

7d
Prognostic Value of Combined Carbohydrate Antigen 19-9 and Duke Pancreatic Monoclonal Antigen Type 2 Assessment in Biliary Tract Cancer. (PubMed, Ann Surg Oncol)
Concurrent normal CA19-9 and DUPAN-2 levels independently predicted favorable outcomes. Combined preoperative biomarker assessment may contribute to prognostic stratification of BTCs, including among patients with Lewis antigen negativity or impaired FUT3 function.
Journal
|
FUT3 (Fucosyltransferase 3) • CA 19-9 (Cancer antigen 19-9)
8d
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays (clinicaltrials.gov)
P=N/A, N=420, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting
Enrollment open
|
5-fluorouracil • oxaliplatin • leucovorin calcium
23d
Role of MeCP2 in Shaping the Histopathological Heterogeneity of Ampullary Carcinoma. (PubMed, Acta Histochem Cytochem)
EMSA further demonstrated that hydroxymethylated CpG sites within the VCAN promoter specifically recruited MeCP2, which interacted with CREB to activate VCAN transcription. These findings reveal a dual role of MeCP2: its loss contributes to epithelial heterogeneity, whereas its retained function in CAFs promotes stromal remodeling through VCAN activation.
Journal
|
CDX2 (Caudal Type Homeobox 2) • VCAN (Versican)
1m
Spatial transcriptomics profiling of small intestine adenocarcinoma and adenoma in humans and a murine model with KRASG12D and loss of CDKN2a-p16. (PubMed, Am J Pathol)
A novel genetically engineered mouse model that mimics gastric-type and intestinal-type adenomas and gastric-type SIAC/EDA is reported. Spatial transcriptomics provided a detailed understanding of cellular differentiation lineages, cancer microenvironment related to SIAC subtypes and driving pathways that may be leveraged to identify new molecular tools for pathologic diagnosis and potential targets for precision cancer therapies.
Preclinical • Journal
|
KRAS (KRAS proto-oncogene GTPase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
|
KRAS G12D • KRAS G12
1m
Duodenal ampullary neuroendocrine tumor, high risk gastrointestinal stromal tumor, and gastric leiomyoma in a patient with neurofibromatosis type 1: a rare case report and literature review. (PubMed, Front Oncol)
No adjuvant therapy was administered due to the absence of residual disease and actionable mutations. This case highlights the broad tumor spectrum in NF1 and underscores the importance of comprehensive imaging, multidisciplinary management, and genetic testing for optimal outcomes.
Journal
|
NF1 (Neurofibromin 1)
1m
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers (clinicaltrials.gov)
P=N/A, N=15, Recruiting, University of California, Irvine | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
Trial completion date • Trial primary completion date • Circulating tumor DNA
1m
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes (clinicaltrials.gov)
P=N/A, N=360, Recruiting, Cedars-Sinai Medical Center | Trial completion date: Jun 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Jan 2027
Trial completion date • Trial primary completion date
2ms
Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas. (PubMed, Int J Mol Sci)
In selected fit patients, modified FOLFIRINOX may address mixed phenotypes...Research priorities include ampulla-enriched umbrella trials, explicit AC subcohorts in tissue-agnostic studies, and ctDNA-informed endpoints. This lineage-first, mutation-fast paradigm supports precision care and evidence generation in AC.
Review • Journal • MSi-H Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF V600E • KRAS mutation • MSI-H/dMMR • HER-2 amplification • BRAF V600 • RET fusion
|
5-fluorouracil • irinotecan • leucovorin calcium
2ms
Recurrence patterns and predictors after pancreaticoduodenectomy for ampullary carcinoma. (PubMed, HPB (Oxford))
Recurrence is predominantly systemic and driven by nodal status and CA19‑9, adjuvant chemotherapy mitigates distant failure-particularly in N1-and the identification of delayed gastric emptying as an independent predictor underscores the oncologic importance of perioperative optimization; histologic subtype was not independently prognostic.
Journal
|
CA 19-9 (Cancer antigen 19-9)
2ms
Clinical characteristics of ampullary tumors and analysis of the efficacy and safety of endoscopic papillectomy (ChiCTR2500112237)
P=N/A, N=182, Not yet recruiting, Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital; Department of Gastroenterology, The First Medical Center of
New trial
2ms
The Impact of Braun Anastomosis with Different Lengths of Output Loop on the Major Clinical Outcomes After Pancreatectomy: A Prospective, Randomized, Controlled, Multicenter Clinical Study (ChiCTR2600116777)
P=N/A, N=60, Recruiting, The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University
New trial